{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:17:48Z","timestamp":1776730668012,"version":"3.51.2"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1053\/j.seminhematol.2012.09.003","type":"journal-article","created":{"date-parts":[[2012,10,15]],"date-time":"2012-10-15T19:52:01Z","timestamp":1350330721000},"page":"295-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Low-Risk Myelodysplastic Syndrome: Hematopoietic Growth Factors Erythropoietins and Thrombopoietins"],"prefix":"10.1053","volume":"49","author":[{"given":"Valeria","family":"Santini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2012.09.003_bib1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in MDS","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System (IPPS-R) for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib3","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nrc2047","article-title":"Myelodysplastic syndromes: the complexity of stem-cell diseases","volume":"7","author":"Corey","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood.V89.5.1690","article-title":"Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome","volume":"89","author":"Hoefsloot","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0145-2126(96)00002-1","article-title":"Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes","volume":"20","author":"Mittelman","year":"1996","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(98)00048-4","article-title":"Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myelodysplastic syndrome","volume":"27","author":"Shimizu","year":"1999","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2141.1999.01539.x","article-title":"Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction","volume":"106","author":"Fontenay-Roupie","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib9","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2006-05-023093","article-title":"Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors","volume":"108","author":"Navas","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib10","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3324\/haematol.2010.024349","article-title":"p-ERK1\/2 is a predictive factor of response to erythropoiesis-stimulating agents in low\/int-1 myelodysplastic syndromes","volume":"95","author":"Frisan","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib11","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1158\/1078-0432.CCR-11-0686","article-title":"Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients","volume":"18","author":"Spinelli","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib12","first-page":"11","article-title":"Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome","volume":"16","author":"Ma","year":"2010","journal-title":"BMC Med Genet"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib13","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib14","first-page":"136","article-title":"Quality of life and physicians' perception in myelodysplastic syndromes","volume":"2","author":"Oliva","year":"2012","journal-title":"Am J Blood Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0609.2011.01654.x","article-title":"Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of \u2265120 g\/L with darbepoetin alfa \u00b1 filgrastim or erythrocyte transfusions","volume":"87","author":"Nilsson-Ehle","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2011.049130","article-title":"Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes","volume":"97","author":"Davidoff","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1634\/theoncologist.12-10-1264","article-title":"Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis","volume":"12","author":"Ross","year":"2007","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00277-008-0450-7","article-title":"Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis","volume":"87","author":"Moyo","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/cncr.24090","article-title":"An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach","volume":"115","author":"Mundle","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib20","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib21","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cncr.22221","article-title":"Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies","volume":"107","author":"Straus","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib22","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/annonc\/mdh428","article-title":"Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing","volume":"15","author":"Stasi","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00277-004-0961-9","article-title":"Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome","volume":"84","author":"Aloe Spiriti","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.leukres.2010.05.030","article-title":"Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients","volume":"34","author":"Park","year":"2010","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000166864","article-title":"Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes","volume":"120","author":"Latagliata","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ajh.22111","article-title":"High-dose (40,000 IU twice\/week) alpha recombinant human erythropoietin as single agent in low\/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution","volume":"86","author":"Azzar\u00e0","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib27","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.leukres.2011.05.025","article-title":"Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes","volume":"35","author":"Balleari","year":"2011","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.21316","article-title":"A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes","volume":"8","author":"Gotlib","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2141.2008.07181.x","article-title":"Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes","volume":"142","author":"Gabrilove","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14712591003709713","article-title":"Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond","volume":"10","author":"Kelaidi","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3109\/10428191003728610","article-title":"Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life","volume":"51","author":"Oliva","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib32","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1185\/03007995.2011.561834","article-title":"Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response","volume":"27","author":"Villegas","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2141.2002.03583.x","article-title":"Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients","volume":"118","author":"Terpos","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00277-005-0044-6","article-title":"Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study","volume":"85","author":"Balleari","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00432-002-0372-z","article-title":"Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes","volume":"128","author":"Kasper","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib36","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib37","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood.V99.5.1578","article-title":"Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes","volume":"99","author":"Stasi","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/leu.2008.362","article-title":"Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes?","volume":"23","author":"Itzykson","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2141.2008.07465.x","article-title":"Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low\/intermediate risk myelodysplastic syndromes","volume":"144","author":"Ferrero","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2141.2012.09125.x","article-title":"Long-term follow-up of myelodysplastic syndrome patients with moderate\/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival","volume":"158","author":"Cris\u00e0","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib41","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-03-415661","article-title":"Combined treatment with lenalidomide and epoetin alfa in lower risk patients with myelodysplastic syndrome","author":"Komrokji","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2012.09.003_bib42","article-title":"Azacitidine in combination with EPO plus G-CSF and Valproic acid rapidly determines hematological improvement in pretreated non responsive IPSS INT-1 MDs patients","volume":"31","author":"Santini","year":"2007","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.leukres.2011.11.019","article-title":"Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?","volume":"36","author":"Itzykson","year":"2012","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.leukres.2012.01.002","article-title":"AZA-ESA combo: a new standard for higher risk MDS?","volume":"36","author":"Mittelman","year":"2012","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.leukres.2005.08.020","article-title":"Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes","volume":"30","author":"Musto","year":"2006","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib46","first-page":"322","article-title":"Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes","volume":"87","author":"Grossi","year":"2002","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CCO.0b013e32833aa9de","article-title":"Erythropoietin in cancer patients: pros and cons","volume":"22","author":"Dicato","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib48","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.leukres.2009.10.022","article-title":"Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes","volume":"34","author":"Musto","year":"2010","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib50","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ajh.21244","article-title":"Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents","volume":"83","author":"Steensma","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3324\/haematol.2011.051755","article-title":"Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes","volume":"97","author":"Smith","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib53","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstr\u00f6m-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib54","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-08-239749","article-title":"Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment","volume":"115","author":"Westers","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib55","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.leukres.2010.01.018","article-title":"Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines","volume":"34","author":"Santini","year":"2010","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6004\/jnccn.2011.0005","article-title":"NCCN clinical practice guidelines in oncology: myelodysplastic syndromes","volume":"9","author":"Greenberg","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2007-08-109488","article-title":"Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology\/American Society of Clinical Oncology clinical practice guideline update","volume":"111","author":"Rizzo","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib58","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.seminhematol.2010.02.006","article-title":"Thrombocytopenia in patients with myelodysplastic syndromes","volume":"47","author":"Bryan","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib59","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib60","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/nbt0906-1044","article-title":"Amgen's TPO mimic faces stiff competition","volume":"24","author":"Lawrence","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib61","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1517\/14712598.8.7.1021","article-title":"The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes","volume":"8","author":"Tiu","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib62","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib63","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-03-274753","article-title":"Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib64","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.25545","article-title":"Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2012.09194.x","article-title":"Leukaemic transformation with romiplostim","volume":"158","author":"Gardner","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib66","first-page":"2772","article-title":"Update of an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS)","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib67","first-page":"117","article-title":"Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo (PBO)-controlled study","volume":"118","author":"Giagounidis","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib68","article-title":"A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine","author":"Greenberg","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib69","first-page":"743","article-title":"Eltrombopag\u2014an oral thrombopoietin agonist","volume":"16","author":"Sharma","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib70","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2165\/11207390-000000000-00000","article-title":"Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia","volume":"71","author":"Garnock-Jones","year":"2011","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib71","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"Will","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib72","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","article-title":"Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation","volume":"120","author":"Roth","year":"2012","journal-title":"Blood"},{"issue":"supp1 470","key":"10.1053\/j.seminhematol.2012.09.003_bib73","article-title":"Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and INT-1 MDS: preliminary results of a prospective randomized, single-blind placebo controlled trial","volume":"97","author":"Oliva","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.09.003_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:50Z","timestamp":1758522110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196312000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0037196312000728"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.09.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Low-Risk Myelodysplastic Syndrome: Hematopoietic Growth Factors Erythropoietins and Thrombopoietins","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}